Lenalidomide (IMiD® Agent)

Proposed Mechanism of Action

Lenalidomide is an oral, small-molecule immunomodulatory agent that directly induces tumor-cell killing and enhances immune function in preclinical studies.1,2


Lenalidomide targets cereblon, a component of the E3 ubiquitin ligase complex, leading to direct tumoricidal and immunomodulatory effects.3-6 Preclinical studies have demonstrated increased activity of lenalidomide in combination with rituximab, an anti-CD20 monoclonal antibody that has been leveraged in the treatment of non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia.7-12 Combinations of lenalidomide and rituximab are being investigated for the treatment of NHL subtypes, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), and marginal zone lymphoma.13-15

Myelodysplastic Syndromes

Haploinsufficiency, caused when only 1 copy of a gene is present, is hypothesized to drive pathogenesis of del(5q) myelodysplastic syndromes (MDS)16-18 and may underlie the specific activity of lenalidomide.19 In myeloid cell lines, haploinsufficiency increases the sensitivity of del5q MDS cells to lenalidomide-mediated degradation of casein kinase 1A1 (CSNK1A1), a gene located in the deleted region of chromosome 5 in del(5q) MDS.20,21

Preclinical and correlative studies in MDS cells suggest that in non-del(5q) MDS, the effects of lenalidomide on cellular progenitors and the microenvironment work together to promote normal erythropoiesis through expansion of progenitor populations,1,22-24 reduction in proinflammatory cytokines,18 and reduction of marrow microvessel density.18

Multiple Myeloma

In preclinical studies, lenalidomide has demonstrated direct tumoricidal and immunomodulatory effects, which are mediated in both myeloma and immune cells by targeting cereblon, a component of the E3 ubiquitin ligase complex.2-6 This interaction triggers proteasome degradation of transcription factors Ikaros and Aiolos, resulting in downregulation of myeloma survival signals, IRF4 and c-Myc, and upregulation of immunoregulatory molecule IL-2.4,6,25

Lenalidomide Hypothesized Mechanism of Action in Multiple Myeloma

Lenalidomide is an IMiD® agent shown in vitro to have direct tumoricidal and immunomodulatory effects in lymphoma, multiple myeloma, and myelodysplastic syndromes.

Lenalidomide by Disease State

Lenalidomide in Lymphoma

  • Post Approval Research Lymphoma Mantle cell lymphoma: Relapsed/refractory (US)
  • Post Approval Research Lymphoma Mantle cell lymphoma: Relapsed/refractory (EU)
  • Phase 3 Lymphoma Diffuse large B-cell (ABC-subtype): First-line
  • Phase 3 Lymphoma Indolent lymphoma: Relapsed/refractory
  • Phase 3 Lymphoma Follicular lymphoma: First-line
  • Post Approval Research Lymphoma Adult T-cell leukemia-lymphoma (Japan)

R2 has demonstrated increased activity in preclinical studies of follicular lymphoma.

The increased immunomodulatory activity of R2 compared with either agent alone combined with the cytotoxic activity of CHOP represent the rationale for investigating R2-CHOP in activated B-cell DLBCL.

Mantle Cell Lymphoma

In preclinical studies, lenalidomide increases mitochondrial release of cytochrome c and activates caspases, resulting in direct MCL tumor cell killing.11,31 In lymphoma cells, the combination of lenalidomide and rituximab increases both direct anti-tumor killing activities of lenalidomide and NK-cell–mediated killing observed with rituximab.10,11 Lenalidomide also increases rituximab-mediated activation of caspases 3, 8, and 911 and increases NK-cell killing capacity through ADCC in these cells.10

Lenalidomide in Multiple Myeloma

  • Post Approval Research Multiple Myeloma Relapsed/refractory
  • Post Approval Research Multiple Myeloma Newly diagnosed
  • Post Approval Research Multiple Myeloma Maintenance

Rationale for Clinical Development

Lenalidomide has shown direct anti-myeloma activity and direct stimulation of immune function in preclinical studies.2,32 Additional preclinical studies demonstrated increased anti-myeloma activity of lenalidomide in combination with dexamethasone and certain proteasome inhibitors and monoclonal antibodies.33-36 Celgene is currently investigating lenalidomide as a foundation for combination with other agents in multiple myeloma.

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.


  1. Komrokji RS, List AF. Semin Oncol. 2011;38:648-657. PMID: 21943671
  2. Borello I. Leuk Res. 2012;36:S3-S12. PMID: 23176722
  3. Revlimid (lenalidomide) capsules, for oral use [package insert]. Summit, NJ: Celgene Corporation; 2017.
  4. Lu G, et al. Science. 2014;343:305-309. PMID: 24292623
  5. Lopez-Girona A, et al. Leukemia. 2012;26:2326-2335. PMID: 22552008
  6. Bjorklund CC, et al. Blood Cancer J. 2015;5:e354. PMID: 26430725
  7. Lagrue K, et al. Blood. 2015;126:50-60. PMID: 26002964
  8. Gribben JG, et al. J Clin Oncol. 2015;33:2803-2811. PMID: 26195701
  9. Ramsay AG, et al. Blood. 2009;114:4713-4720. PMID: 19786615
  10. Reddy N, et al. Br J Haematol. 2008;140:36-46. PMID: 17995965
  11. Zhang L, et al. Am J Hematol. 2009;84:553-559. PMID: 19565649
  12. Rituxan (rituximab) [package insert]. South San Francisco, CA: Genentech, Inc; 2016.
  13. ClinicalTrials.gov. https://clinicaltrials.gov/show/NCT01996865.
  14. ClinicalTrials.gov. https://clinicaltrials.gov/show/NCT01938001.
  15. ClinicalTrials.gov. https://clinicaltrials.gov/show/NCT02285062.
  16. Boultwood J, et al. Blood. 2002;99:4638-4641. PMID: 12036901
  17. Horrigan SK, et al. Blood. 1996;88:2665-2670. PMID: 8839861
  18. Ebert BL, et al. Nature. 2008;451:335-339. PMID: 18202658
  19. Wei S, et al. Proc Natl Acad Sci U S A. 2009;106:12974-12979. PMID: 19470455
  20. Hollenbach P, et al. Blood. 2014;124 [abstract 3606].
  21. Fink EC, et al. Blood. 2014;124 [abstract 4].
  22. List AF, et al. Cancer Control. 2006;13(suppl):4-11. PMID: 17242661
  23. Verhelle D, et al. Cancer Res. 2007;67:746-755. PMID: 17234786
  24. Mouthouh-de Parseval LA, et al. J Clin Invest. 2008;118:248-258. PMID: 18064299
  25. Krönke J, et al. Science. 2014;343:301-305. PMID: 24292625
  26. Rawal S, et al. Blood. 2012;120 [poster 2766].
  27. Haslett PAJ, et al. J Infect Dis. 2003;187:946-955. PMID: 12660941
  28. Zhang LH, et al. Br J Haematol. 2013;160:487-502. PMID: 23252516
  29. Yang Y, et al. Cancer Cell. 2012;21:727-737.
  30. Shaffer AL, et al. Clin Cancer Res. 2009;15:2954-2961. PMID: 19383829
  31. Qian Z, et al. Leuk Res. 2011;35:380-386. PMID: 21047686
  32. Borello I. Leuk Res. 2012;36:S3-S12. PMID: 23176722
  33. Gandhi AK, et al. Br J Haematol. 2014;164:811-821. PMID: 24328678
  34. Gandhi AK, et al. Curr Cancer Drug Targets. 2010;10:155-167. PMID: 20088798
  35. Celgene. Data on file (Report 8769-001).
  36. Chauhan D, et al. Blood. 2010:1164906-4915. PMID: 20805366
  37. Das DS, et al. Br J Haematol. 2015;171:798-812. PMID: 26456076